Panacea Biotec, a leading Indian pharmaceutical and biotechnology company, has made a significant stride in the global healthcare space with the inclusion of its proprietary adjuvant, EmulsiPan, in the prestigious CEPI (Coalition for Epidemic Preparedness Innovations) Adjuvant Library. This move not only acknowledges the scientific value of EmulsiPan but also marks Panacea’s entry into the global adjuvant commercialisation space.

What is EmulsiPan and Why Is It Important?

EmulsiPan is a sterile oil-in-water emulsion adjuvant, uniquely designed through nano-emulsification of squalene, a biodegradable and biocompatible compound found in plants and humans, with carefully selected surfactants and buffers. It is ready-to-use, supplied in a 10 mL USP Type I glass vial, and stable for over two years when stored at 2-8°C.

The significance of EmulsiPan lies in its dose-sparing effect and ability to enhance vaccine efficacy — two crucial attributes in today’s vaccine development efforts, especially during pandemic response or for low-resource settings. With its user-friendly formulation and regulatory preparedness, EmulsiPan stands as a versatile adjuvant platform for researchers and developers alike.

Backed by Science and Trusted Collaborations

EmulsiPan has already been a trusted component in multiple vaccine research programs, including:

• Non-human primate (NHP) challenge studies for Sarbecoronavirus vaccine candidates at the California Institute of Technology (Caltech)

• Betacoronavirus vaccine development in collaboration with BRIC-Translational Health Science and Technology Institute (THSTI), funded by CEPI

These collaborations underscore EmulsiPan’s scientific merit, adaptability, and compatibility with various vaccine platforms.

A History of Innovation

Though EmulsiPan was initially developed in 2009 as part of PandyFlu—Panacea Biotec’s H1N1 influenza vaccine—it has since evolved into a robust and adaptable adjuvant. At the height of the H1N1 pandemic, Panacea demonstrated its ability to rapidly develop the adjuvant, set up a cGMP facility, and deliver a vaccine-adjuvant combo on a fast-track basis.

This capacity for swift innovation and manufacturing scalability remains crucial in today's unpredictable public health environment.

Global Recognition through CEPI

Being listed in the CEPI Adjuvant Library is a seal of approval that EmulsiPan meets rigorous scientific and safety standards necessary for human vaccine development. This library is a global initiative meant to accelerate vaccine R&D by offering ready-to-use, thoroughly vetted adjuvants to researchers worldwide.

This not only gives EmulsiPan global visibility but also assures vaccine developers of its reliability and performance.

Commercialisation and Open Access

With the growing demand for efficient, safe, and scalable adjuvants, Panacea Biotec’s foray into the commercial production and distribution of EmulsiPan is timely. The global adjuvant market, projected to reach USD 4.8 billion by 2028, spans uses in human vaccines, animal vaccines, and even oncological therapies.

Importantly, EmulsiPan does not carry licensing fees, making it accessible and affordable to global research institutions and biotech firms. Interested parties can now reach out to Panacea Biotec for both research collaborations and commercial applications.

Comments from Leadership

On the occasion, Dr. Rajesh Jain, Chairman and Managing Director of Panacea Biotec, expressed his pride:

“It is with great pride that we announce the availability of EmulsiPan, a ready-to-use dose-sparing adjuvant designed to enhance vaccine efficacy and support global public health initiatives. Such investments showcase our commitment to research and development that prepare us for every possibility.”

This statement reaffirms Panacea Biotec’s vision to lead through innovation, especially in fields that impact global health equity and preparedness.

Strategic Impact on Vaccine Ecosystem

By offering a cGMP-manufactured, stable, and validated adjuvant, Panacea Biotec addresses a long-standing gap in adjuvant accessibility—often a bottleneck in early-stage vaccine development. Especially for small biotechs and academic institutions, EmulsiPan offers a ready-to-integrate solution.

Furthermore, its non-licensing model ensures that life-saving research isn’t stalled due to cost or proprietary barriers.

Applications Beyond Human Vaccines

In addition to use in influenza and coronavirus vaccine candidates, EmulsiPan’s formulation is well-suited for animal vaccines and biological therapies, particularly in the oncology space, where immune modulation plays a key role.

Its broad-spectrum use cases make it a multi-sectoral asset in biopharmaceutical research.

Conclusion: A Global Step Forward

The inclusion of EmulsiPan in CEPI’s Adjuvant Library signals a new chapter for Panacea Biotec as it enters the global adjuvant market. With a proven formulation, scientific endorsements, and commercial readiness, EmulsiPan is poised to empower global vaccine development, ensuring that innovative health solutions remain accessible, effective, and equitable.

Panacea Biotec continues to demonstrate that India’s pharmaceutical sector is not just keeping pace with global health challenges, but is also leading from the front.

Panacea Biotec’s EmulsiPan is more than just a product — it is a platform for progress in the world of immunisation and global health. As the world prepares for future pandemics and persistent infectious diseases, innovations like EmulsiPan will be critical components of our collective defense.

The Upcoming IPOs in this week and coming weeks are Sacheerome Limited, Ganga Bath Fittings, Victory Electric Vehicles International, Wagons Learning.

The Current active IPO are 3B Films

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.